G9a Inhibition Enhances Checkpoint Inhibitor Blockade Response in Melanoma.
Gregory M KellyFares Al-EjehRobert McCuaigFrancesco CascielloNabilah Ahmad KamalBlake FergusonAntonia L PritchardSayed AliInes P SilvaJames S WilmottGeorgina V LongRichard A ScolyerSudha RaoNicholas K HaywardFrank GannonJason S LeePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
Checkpoint inhibitor blockade response is limited to a subset of the patient population. These results have implications for the development of LC3B as a predictive biomarker of checkpoint inhibitor blockade to guide patient selection, as well as G9a inhibition as a strategy to extend the proportion of patients responding to immunotherapy.